[{"address1": "480 Pleasant Street", "address2": "Suite A-210", "city": "Watertown", "state": "MA", "zip": "02472", "country": "United States", "phone": "617 926 5000", "fax": "617 926 5050", "website": "https://eyepointpharma.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.", "fullTimeEmployees": 121, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jay S. Duker M.D.", "age": 64, "title": "President, CEO & Director", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 1294494, "exercisedValue": 0, "unexercisedValue": 3270523}, {"maxAge": 1, "name": "Mr. George O. Elston", "age": 58, "title": "Executive VP & CFO", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 905344, "exercisedValue": 0, "unexercisedValue": 1614510}, {"maxAge": 1, "name": "Dr. John B. Landis M.S., Ph.D.", "age": 70, "title": "Interim Head of R&D and Director", "yearBorn": 1953, "fiscalYear": 2023, "totalPay": 67500, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael J. Maciocio", "title": "Senior Vice President of Manufacturing & Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ron I. Honig Esq.", "title": "Chief Legal Officer & Company Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jennifer  Leonard", "title": "Chief People Officer & Senior VP of  IT", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David Scott Jones M.A.", "age": 56, "title": "Senior VP & Chief Commercial Officer", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 672084, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael  Pine", "age": 46, "title": "Chief Business Officer", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 764853, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Isabelle  Lefebvre", "title": "Chief Regulatory Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marcia  Sellos-Moura Ph.D.", "title": "Senior VP and Head of Development & Program Management", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 5, "compensationRisk": 7, "shareHolderRightsRisk": 4, "overallRisk": 6, "governanceEpochDate": 1730419200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 11.76, "open": 11.88, "dayLow": 11.34, "dayHigh": 12.4699, "regularMarketPreviousClose": 11.76, "regularMarketOpen": 11.88, "regularMarketDayLow": 11.34, "regularMarketDayHigh": 12.4699, "beta": 1.59, "forwardPE": -3.8164558, "volume": 839198, "regularMarketVolume": 839198, "averageVolume": 739290, "averageVolume10days": 1497090, "averageDailyVolume10Day": 1497090, "bid": 12.02, "ask": 12.12, "bidSize": 200, "askSize": 300, "marketCap": 821944512, "fiftyTwoWeekLow": 5.86, "fiftyTwoWeekHigh": 30.99, "priceToSalesTrailing12Months": 16.311337, "fiftyDayAverage": 9.2264, "twoHundredDayAverage": 14.6648, "currency": "USD", "enterpriseValue": 388475616, "profitMargins": -1.72295, "floatShares": 35855595, "sharesOutstanding": 68154600, "sharesShort": 9171397, "sharesShortPriorMonth": 9101038, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.1714, "heldPercentInsiders": 0.011410001, "heldPercentInstitutions": 0.86087996, "shortRatio": 15.84, "shortPercentOfFloat": 0.2009, "bookValue": 4.377, "priceToBook": 2.755312, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -86821000, "trailingEps": -1.78, "forwardEps": -3.16, "lastSplitFactor": "1:10", "lastSplitDate": 1607472000, "enterpriseToRevenue": 7.709, "enterpriseToEbitda": -4.025, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "EYPT", "underlyingSymbol": "EYPT", "shortName": "EyePoint Pharmaceuticals, Inc.", "longName": "EyePoint Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1106836200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "564ca7d9-104b-3085-b6a2-17354e99fc88", "gmtOffSetMilliseconds": -18000000, "currentPrice": 12.06, "targetHighPrice": 68.0, "targetLowPrice": 18.0, "targetMeanPrice": 36.9, "targetMedianPrice": 32.5, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 280248000, "totalCashPerShare": 5.236, "ebitda": -96526800, "totalDebt": 23294000, "quickRatio": 4.535, "currentRatio": 4.749, "totalRevenue": 50391000, "debtToEquity": 10.203, "revenuePerShare": 1.08, "returnOnAssets": -0.24359, "returnOnEquity": -0.60806, "freeCashflow": -33153750, "operatingCashflow": -89662000, "revenueGrowth": 0.041, "grossMargins": -0.54825, "ebitdaMargins": -1.91556, "operatingMargins": -3.6452498, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-11-04"}]